# Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

> **NCT07154901** · PHASE1 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 50 (estimated)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** Opemalirsen (AZD2373)

## Key facts

- **NCT ID:** NCT07154901
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-18
- **Primary completion:** 2026-06-15
- **Final completion:** 2026-06-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07154901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07154901, "Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07154901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*